Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Model systems for the discovery and development of antiarrhythmic drugs

Mechanistic and Therapeutic Perspectives for Cardiac Arrhythmias: Beyond Ion Channels

New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models

Animal models of arrhythmia: classic electrophysiology to genetically modified large animals

Multicellular In vitro Models of Cardiac Arrhythmias: Focus on Atrial Fibrillation

Cardiovascular disease models: A game changing paradigm in drug discovery and screening

Animal models for atrial fibrillation: clinical insights and scientific opportunities

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Combined in silico model of cardiac electrophysiological activity and modulation by the autonomic nervous system

Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation

Potential Pathogenesis Discovery of Arrhythmia Based on Cardiac Electrophysiological Models: Research Progress

Ventricular Arrhythmias in Ischemic Cardiomyopathy—New Avenues for Mechanism-Guided Treatment

Anti‐arrhythmic investigations in large animal models of atrial fibrillation

Small Mammalian Animal Models of Heart Disease.

The ECG in cardiovascular-relevant animal models of electrophysiology

Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for modeling cardiac arrhythmias: strengths, challenges and potential solutions

Computational models of atrial cellular electrophysiology and calcium handling, and their role in atrial fibrillation

Use of animal models of atrial fibrillation in the study of cellular and molecular therapy

The canine chronic atrioventricular block model in cardiovascular preclinical drug research

Assessment of Drug-Induced Proarrhythmia: the Importance of Study Design in the Rabbit Left Ventricular Wedge Model.

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment